公开(公告)号：US20160305931A1

公开(公告)日：2016-10-20

申请号：US14795163

申请日：2015-07-09

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Byung Hwa JUNG ,  Jong Min CHOI ,  Hong Seog SEO

IPC: G01N33/49

CPC classification number: G01N33/492 ,  G01N33/6893 ,  G01N2405/02 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2570/00 ,  G01N2800/324

Abstract: The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

Abstract translation: 本公开提供了使用一种或多种选自色氨酸，高丝氨酸，脂肪酸（16:1），脂肪酸（18：0），脂肪酸（18：1），脂肪酸 （18:2），脂肪酸（22:6），磷脂酰胆碱（PC）（34:2），PC（34:3），溶血磷脂酰胆碱（溶血卵磷脂）（16：0），溶血卵磷脂（18：0） 20：3），lysoPC（20：4），溶血卵磷脂（22：6），单甘油酯（18：1：0：0/0：0）和鞘磷脂（d18：2/16：0） 通过体内水平分析简单准确地诊断急性冠状动脉综合征以及发病前的症状。

公开(公告)号：US20180156774A1

公开(公告)日：2018-06-07

申请号：US15601262

申请日：2017-05-22

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Byung Hwa JUNG ,  Jong Min CHOI ,  Hong Seog SEO

IPC: G01N33/49

CPC classification number: G01N33/492 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/60

Abstract: The present disclosure relates to a method and a diagnostic kit for diagnosing stable angina and acute myocardial infarction early through simple blood testing and checking of clinical parameters. Unlike conventional diagnostic methods, stable angina can be diagnosed as distinguished from acute myocardial infarction according to the present disclosure by using one diagnostic platform based on the change in the in-vivo levels of biological metabolites having different metabolic pathways and clinical parameters as well as medications affecting the onset and progress of the disease through multivariable analysis.

公开(公告)号：US20150198582A1

公开(公告)日：2015-07-16

申请号：US14185300

申请日：2014-02-20

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Byung Hwa JUNG ,  Jong Min CHOI

IPC: G01N33/49 ,  G01N30/72

CPC classification number: G01N33/492 ,  G01N30/72 ,  G01N33/92 ,  G01N2800/324 ,  Y10T436/24

Abstract: Biological metabolites LysoPC (18:0), LysoPC (20:3), fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2) and fatty acid (22:6) according to the present disclosure allow for simple and accurate diagnosis of a cardiovascular disease since their level in the blood of a subject increases or decreases if the subject has a cardiovascular disease such as myocardial infarction or angina. In addition, whereas the existing biomarkers can diagnose only whether myocardial infarction occurs or not, the biological metabolites according to the present disclosure can diagnose not only myocardial infarction but also unstable angina occurring prior to the onset of myocardial infarction stage by stage.

Abstract translation: 生物代谢物LysoPC（18：0），LysoPC（20：3），脂肪酸（16：1），脂肪酸（18：0），脂肪酸（18：1） （22：6）允许对心血管疾病进行简单和准确的诊断，因为如果受试者患有心血管疾病如心肌梗塞或心绞痛，则他们的受试者的血液中的水平增加或减少。 另外，现有的生物标志物只能诊断心肌梗塞是否发生，根据本发明的生物代谢物不仅可以诊断心肌梗死，还可以诊断心肌梗死发生阶段之前发生的不稳定型心绞痛。